Basic research aiming for clinical application of 5-aminolevulinic acid in musculoskeletal sarcomas

Not Applicable

• Conditions: bone and soft tissue sarcomas

• Registration Number: JPRN-UMIN000022275
• Lead Sponsor: Saitama Medical University International Medical Center

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-01-01
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

Not provided

Exclusion Criteria

1. Having difficulty in taking medication 2. Still having severe adverse effects of previous treatment for sarcomas 3. Having un-controlled infection 4. Severe complications, such as malignant hypertension, severe congestive heart failure, myocardial infarction within 3 months, terminal cirrhosis, un-controlled diabetes, severe pulmonary fibrosis, active interstitial pneumonia 5. Allergy to porphyrin-related substances 6. Porphyria 7. Other active cancer including hematologic malignancy

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
1. The strength of fluorescent signal induced by PPIX in both cell lines and clinical specimens

Secondary Outcome Measures

Name	Time	Method
2. The degree of expression of the aforementioned genes in both cell lines and clinical specimens